PRF Technologies (PRFX) Assets Average (2021 - 2025)
PRF Technologies (PRFX) posted quarterly Assets Average of $11.6 million for Q4 2025, up 203.46% year-on-year from $3.8 million in Q4 2024, and up 47.64% on a QoQ basis from $7.8 million in Q2 2025.
PRF Technologies (PRFX) Assets Average (2021 - 2025) Analysis & Trends
PRF Technologies (PRFX) has reported Assets Average for 5 consecutive years, with $11.6 million the latest figure, recorded in Q4 2025.
- Quarterly Assets Average rose 203.46% year-over-year to $11.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.6 million (up 203.46% YoY) and the FY2025 annual result came in at $8.3 million, up 236.24% from the prior year.
- Assets Average climbed to $11.6 million in Q4 2025 per PRFX's latest filing, from $7.8 million in the prior quarter.
- Over the last five years, Assets Average for PRFX reached as high as $20.6 million in Q2 2021 and fell as low as $2.9 million in Q1 2024.
- A 5-year average of $12.4 million and a median of $11.6 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average plunged 74.69% — and 2025, when it soared 203.46%.
- Year by year, Assets Average stood at $19.7 million in 2021, then slumped by 31.03% to $13.6 million in 2022, then tumbled by 58.51% to $5.6 million in 2023, then tumbled by 32.32% to $3.8 million in 2024, then surged by 203.46% to $11.6 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $11.6 million, $7.8 million, and $3.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.32 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 99.52 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 7.30 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 68.63 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 37.01 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.77 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.29 Bn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | 11.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.58 Mn |
| Jun 30, 2025 | 7.84 Mn |
| Dec 31, 2024 | 3.82 Mn |
| Jun 30, 2024 | 4.24 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Dec 31, 2023 | 5.64 Mn |
| Sep 30, 2023 | 9.60 Mn |
| Jun 30, 2023 | 9.37 Mn |
| Mar 31, 2023 | 11.37 Mn |
| Dec 31, 2022 | 13.59 Mn |
| Sep 30, 2022 | 15.42 Mn |
| Jun 30, 2022 | 16.85 Mn |
| Mar 31, 2022 | 18.39 Mn |
| Dec 31, 2021 | 19.71 Mn |
| Sep 30, 2021 | 20.09 Mn |
| Jun 30, 2021 | 20.60 Mn |
| Mar 31, 2021 | 19.58 Mn |